 |
 |
|
|
RESÚMENES JUNIO 2007 |
Psychotic Disorders & Antipsychotics
(Haga un click en la información del journal para acceder al resúmen)
Ziprasidone Outcome and Tolerability:
A Practical Clinical Trial With Plasma Drug Levels
M. C. Mauri, A. Colasanti, M. Rossattini,
L. S. Volonteri, F. Dragogna, A. Fiorentini,
A. Fiorentini, A. Valli,
P. Papa
Pharmacopsychiatry 2007; 40: 89-92
A Study of Genetic (CYP2D6 and ABCB1) and Environmental (Drug
Inhibitors and Inducers) Variables That May Influence Plasma Risperidone Levels
J. de Leon, M. T. Susce, R.-M. Pan, P. J. Wedlund,
M. L. Orrego, F. J. Diaz
Pharmacopsychiatry 2007; 40: 93-102
Effects of Comedication on the Serum Levels of Aripiprazole:
Evidence from a Routine Therapeutic Drug Monitoring Service
I. Castberg, O. Spigset
Pharmacopsychiatry 2007; 40: 107-110
The Association between
Exposure to COX-2 Inhibitors and Schizophrenia Deterioration. A Nested Case-Control
Study
P. Stolk, P. C. Souverein, H. G. M. Leufkens,
J. G. Weil, A. C. G. Egberts, E. R. Heerdink
Pharmacopsychiatry 2007; 40: 111-115
Oral
Cholinesterase Inhibitor Add-on Therapy for Cognitive Enhancement in
Schizophrenia: A Quantitative Systematic Review, Part I
Chouinard, Sylvie; Sepehry,
Amir Ali; Stip, Emmanuel
Clinical Neuropharmacology. 30(3):169-182, May/June 2007
Differential
effects of typical and atypical antipsychotics on
brain myelination in schizophrenia
George Bartzokis, Po H. Lu, Keith H. Nuechterlein,
Michael Gitlin, Clarissa Doi,
Nancy EdwardsChristopher Lieu, Lori L. Altshuler
Schizophrenia
Research.
Volume 93, Issues 1-3, July 2007, Pages 13-22
A single 20 mg
dose of dihydrexidine (DAR-0100), a full dopamine D1
agonist, is safe and tolerated in patients with schizophrenia
Mark S. George,
Christine E. Molnar, Emily L. Grenesko, Berry
Anderson, Qiwen Mu, Kevin
Johnson, Ziad Nahas,
Michael Knable, Prabhavathi
Fernandes, Jorge Juncos, Xuemei
Huang, David E. Nichols and Richard B. Mailman
Schizophrenia
Research.
Volume 93, Issues 1-3, July 2007, Pages 42-50
Weight gain in
newly diagnosed first-episode psychosis patients and healthy comparisons:
One-year analysis
Martin Strassnig, Jean Miewald,
Matcheri Keshavan and Rohan Ganguli
Schizophrenia
Research.
Volume 93, Issues 1-3, July 2007, Pages 90-98
Metformin
as an adjunctive treatment to control body weight and metabolic dysfunction
during olanzapine administration: A multicentric, double-blind, placebo-controlled trial
Trino Baptista, Nairy Rangel, Virginia Fernández, Edgardo Carrizo, Yamily El Fakih, Euderruh Uzcátegui, Tatiana Galeazzi, María A. Gutiérrez, Mercedes Servigna,
Adriana Dávila, Marycelvia Uzcátegui, Ana Serrano, Lisette
Connell, Serge Beaulieu and Enma Araujo
de Baptista
Schizophrenia
Research.
Volume 93, Issues 1-3, July 2007, Pages 99-108
The effect of lamotrigine augmentation of clozapine
in a sample of treatment-resistant schizophrenic patients: A double-blind,
placebo-controlled study
R. Zoccali, M.R. Muscatello, A.
Bruno, R. Cambria, U. Micò, E. Spina
and M. Meduri
Schizophrenia
Research.
Volume 93, Issues 1-3, July 2007, Pages 109-116
Efficacy, safety
and early response of paliperidone extended-release
tablets (paliperidone ER): Results of a 6-week,
randomized, placebo-controlled study
Michael Davidson,
Robin Emsley, Michelle Kramer, Lisa Ford, Guohua Pan, Pilar Lim and Mariëlle Eerdekens
Schizophrenia
Research.
Volume 93, Issues 1-3, July 2007, Pages 117-130
Bone mineral
density changes over a year in young females with schizophrenia: Relationship
to medication and endocrine variables
Schizophrenia
Research.
Volume 93, Issues 1-3, July 2007, Pages 136-143
Double-blind donepezil–placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: A pilot
study
S. Craig Risch, Michael D. Horner, Susan R. McGurk,
Simmy Palecko, John S.
Markowitz, Ziad Nahas and
C. Lindsay DeVane
Schizophrenia
Research.
Volume 93, Issues 1-3, July 2007, Pages 131-135
Remission in
prognosis of functional outcome: A new dimension in the treatment of patients
with psychotic disorders
Lars Helldin, John M. Kane, Ulla Karilampi,
Torsten Norlander and
Trevor Archer
Schizophrenia
Research.
Volume 93, Issues 1-3, July 2007, Pages 160-168
The structure of
psychosis revisited: The role of mood symptoms
Marco P.M. Boks, Stuart Leask, Jeroen K. Vermunt and René S.
Kahn
Schizophrenia
Research.
Volume 93, Issues 1-3, July 2007, Pages 178-185
Repetitive transcranial magnetic stimulation for negative symptoms of
schizophrenia: A randomized controlled pilot study
Andrew Mogg, Rick Purvis, Savitha Eranti, Faith Contell, John P.
Taylor, Timothy Nicholson, Richard G. Brown and Declan M. McLoughlin
Schizophrenia
Research.
Volume 93, Issues 1-3, July 2007, Pages 221-228
The effects of
genetic liability for schizophrenia and maternal smoking during pregnancy on
obstetric complications
Lauren M. Ellman, Matti Huttunen,
Jouko Lönnqvist and Tyrone
D. Cannon
Schizophrenia
Research.
Volume 93, Issues 1-3, July 2007, Pages 229-236
Neurocognitive Effects of Antipsychotic
Medications in Patients With Chronic Schizophrenia in
the CATIE Trial
Richard S. E. Keefe, Robert M. Bilder, Sonia M. Davis, Philip D. Harvey, Barton W. Palmer,
James M. Gold, Herbert Y. Meltzer, Michael F. Green, George Capuano, T. Scott
Stroup, Joseph P. McEvoy, Marvin S. Swartz, Robert A.
Rosenheck, Diana O. Perkins, Clarence E. Davis, John
K. Hsiao, Jeffrey A. Lieberman, for the CATIE Investigators and the Neurocognitive Working Group
Arch Gen Psychiatry. 2007;64:633-647
Effect of olanzapine
or risperidone treatment on some cognitive functions
in a one-year follow-up of schizophrenia outpatients with prominent negative
symptoms
Gurpegui M, Alvarez E, Bousoño M, Ciudad A, Carlos Gómez J, Olivares JM
Eur Neuropsychopharmacol. 2007
May 30; [Epub ahead of print]
An analysis of safety and tolerability data
from controlled, comparative studies of quetiapine in
patients with schizophrenia, focusing on extrapyramidal
symptoms
Kristina Timdahl,
Anders Carlsson, Göran Stening
Human
Psychopharmacology: Clinical and Experimental. Early View; Published Online: 1 Jun 2007
Thirty-five
months experience of risperidone long-acting
injection in a UK psychiatric service including a mirror-image analysis of
in-patient care
O. S. Niaz, P. M. Haddad
Acta Psychiatrica Scandinavica 2007; 116 (1), 36–46
Clinical
epidemiologic first-episode psychosis: 1-year outcome and predictors
E. Simonsen, S. Friis,
U. Haahr, J. O. Johannessen,
T. K. Larsen, I. Melle, S. Opjordsmoen,
B. R. Rund, P. Vaglum, T. McGlashan
Acta Psychiatrica Scandinavica 2007; 116 (1), 54–61
Prevalence
and correlates of comorbidity 8 years after a
first psychotic episode
S. Farrelly, M. G. Harris, L. P. Henry, R.
Purcell, A. Prosser, O. Schwartz, H. Jackson, P. D. McGorry
Acta Psychiatrica Scandinavica 2007; 116 (1), 62–70
The
Negative Syndrome as a Dimension: Factor Analyses of PANSS in Major Depressive
Disorder and Organic Brain Disease Compared With Negative Syndrome Structures
Found in the Schizophrenia Literature
Milak, Matthew S; Aniskin,
Dmitry B; Eisenberg, Daniel P; Prikhojan, Alexander;
Cohen, Lisa J; Yard, Samantha S. BA; Galynker, Igor I
Cognitive & Behavioral
Neurology.
20(2):113-120, June 2007
Comparison of Older
Patients With Bipolar Disorder and
Schizophrenia/Schizoaffective Disorder
Sanjay Gupta, Charles H. Steinmeyer, Kari
Lockwood, Barbara Lentz, and Kay Schultz
Am J Geriatr
Psychiatry 15:627-633, July 2007
What Is the Best Approach to
Treating Schizophrenia in Developing Countries?
Vikram Patel,
Saeed Farooq, R. Thara
PLoS Medicine | June 2007 | Volume 4 | Issue 6 | e159
TEXTO GRATUITO
Neuropsychological
Functioning in Bipolar Disorder and Schizophrenia
David J. Schretlen, Nicola G. Cascella,
Stephen M. Meyer, Lisle R. Kingery, S. Marc Testa, Cynthia A. Munro, Ann E. Pulver,
Paul Rivkin, Vani A. Rao, Catherine M. Diaz-Asper,
Faith B. Dickerson, Robert H. Yolken and Godfrey D. Pearlson
Biological
Psychiatry. Volume 62, Issue 2, 15 July 2007, Pages 179-186
Rapid dose initiation of quetiapine
for the treatment of acute schizophrenia and schizoaffective disorder: a randomised, multicentre,
parallel-group, open study
Giuseppina Boidi,
Maurizio Ferro
Human
Psychopharmacology: Clinical and Experimental. Volume 22,
Issue 5, Pages 299 - 306
Do formulation switches exacerbate existing
medical illness? Results of an open-label transition to orally disintegrating risperidone tablets
Pierre Chue, Rosanna S. Prinzo, Carin E. Binder
Human
Psychopharmacology: Clinical and Experimental. Volume 22,
Issue 5, Pages 307 - 314
An analysis of safety and tolerability data
from controlled, comparative studies of quetiapine in
patients with schizophrenia, focusing on extrapyramidal
symptoms
Kristina Timdahl,
Anders Carlsson, Göran Stening
Human
Psychopharmacology: Clinical and Experimental. Volume 22,
Issue 5, Pages 315 - 325
Dyslipidemia and Schizophrenia
Tilman Wetterling, Barbara Schneider, Bernhard
Weber
Psychiat Prax 2007; 34: 223-229
Adding or Switching
Antipsychotic Medications in Treatment-Refractory Schizophrenia
Julie Kreyenbuhl, Steven C. Marcus, Joyce C.
West, Joshua Wilk, and Mark Olfson
Psychiatr Serv
58:983-990, July 2007
Clozapine-Induced Hypersalivation:
A Review of Treatment Strategies
Sanjeev Sockalingam, Chekkera Shammi, Gary Remington
Can J Psychiatry 2007;52:377–384
TEXTO GRATUITO
Epidemiologic
studies about association of mental disorders and metabolic syndrome
Teixeira,
P.J.R.; Rocha, F.L
Rev. Psiq.
Clín. 34 (1); 28-38, 2007
TEXTO GRATUITO